Slamon, who is the director of both
A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.
The … Read more
Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.
One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more
A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more
Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more
The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further … Read more
Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.
There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more
Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.
Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more
With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more
The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more
In the treatment of advanced ovarian cancer, PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), are stealing the limelight, explains Dennis Scribner, MD.
In an interview with Targeted Oncology, Scribner, a gynecologic oncologist at Arizona Oncology, discussed … Read more
Teri Woodhull is decidedly proactive. A strong family history of breast cancer led her to undergo a preventive bilateral mastectomy at age 30. Seventeen years later, she was diagnosed with stage 3b high-grade serous epithelial ovarian cancer.
“I do have … Read more
The ovarian cancer treatment paradigm underwent another transformation near the end of 2016 with the FDA approval of the PARP inhibitor rucaparib (Rubraca) for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of … Read more
Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.
Results showed a median PFS of … Read more
Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more